Entry |
|
Name |
Ranitidine (USAN/INN); Ranitidine (TN) |
Formula |
C13H22N4O3S
|
Exact mass |
314.1413
|
Mol weight |
314.41
|
Structure |

|
Simcomp |
|
Class |
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
Transporter substrate
DG02854 SLC22A2 substrate
Transporter inhibitor
DG02863 SLC22A2 inhibitor
|
Remark |
Product (DG00018): | D00673<US> |
|
Efficacy |
Anti-ulcerative, H2 receptor antagonist |
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
|
Metabolism |
Transporter: SLC22A2 [HSA: 6582]
|
Interaction |
CYP inhibition: CYP2D6 [HSA: 1565], CYP3A [HSA: 1576 1577 1551]
Transporter inhibition: SLC22A2 [HSA: 6582]
|
Structure map |
map07227 | Histamine H2/H3 receptor agonists/antagonists |
|
Other map |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BA H2-receptor antagonists
A02BA02 Ranitidine
D00422 Ranitidine (USAN/INN)
Risk category of Japanese OTC drugs [BR:br08312]
First-class OTC drugs
Inorganic and organic chemicals
Ranitidine
D00422 Ranitidine (USAN/INN)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
DG00018 Ranitidine
D00422 Ranitidine
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00018 Ranitidine
D00422 Ranitidine
DG02852 CYP3A/CYP3A4 inhibitor
DG00018 Ranitidine
D00422 Ranitidine
Transporter substrate
DG02854 SLC22A2 substrate
DG00018 Ranitidine
D00422 Ranitidine
Transporter inhibitor
DG02863 SLC22A2 inhibitor
DG00018 Ranitidine
D00422 Ranitidine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Histamine
HRH2
D00422 Ranitidine (USAN/INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00422
Drug transporters
D00422
Rx-to-OTC switch list in the USA [br08315.html]
D00422
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01481 Histamine receptor H2 antagonist
DG00018 Ranitidine
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00018 Ranitidine
DG02852 CYP3A/CYP3A4 inhibitor
DG00018 Ranitidine
Transporter substrate
DG02854 SLC22A2 substrate
DG00018 Ranitidine
Transporter inhibitor
DG02863 SLC22A2 inhibitor
DG00018 Ranitidine
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 21
1 C8y C 19.0765 -23.1392
2 O2x O 20.1949 -23.9781
3 C8x C 19.4959 -21.8111
4 C1b C 17.8182 -23.8382
5 C8y C 21.3133 -23.1392
6 C8x C 20.8939 -21.8111
7 N1c N 16.6298 -23.1392
8 C1b C 22.5017 -23.8382
9 C1a C 15.4415 -23.8382
10 C1a C 16.6298 -21.7412
11 S2a S 23.6900 -23.1392
12 C1b C 24.9482 -23.8382
13 C1b C 26.1366 -23.1392
14 N1b N 27.3249 -23.8382
15 C2c C 28.5831 -23.1392
16 C2b C 29.7715 -23.8382
17 N1b N 28.5831 -21.7412
18 N2b N 30.9599 -23.1392 #+
19 C1a C 27.3249 -21.0422
20 O3a O 30.9599 -21.7412 #-
21 O3a O 32.2181 -23.8382
BOND 21
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 3 6 1
6 4 7 1
7 5 8 1
8 7 9 1
9 7 10 1
10 8 11 1
11 11 12 1
12 12 13 1
13 13 14 1
14 14 15 1
15 15 16 2
16 15 17 1
17 16 18 1
18 17 19 1
19 18 20 1
20 18 21 2
21 5 6 2
|